Loading data for PHIO — first visit, this takes a few seconds.
Phio Pharmaceuticals Corp. (PHIO)
NasdaqCM: PHIO
· 即時價格 · USD
1.09
-0.04 (-3.54%)
收盤價： Sep 09, 2026, 8:00 PM
股價、關鍵數字和最新消息，都在這一頁。
Phio Pharmaceuticals Corp.（PHIO）股價、分析與資料
無可用資料
| 買價 | 0.81 |
| 市值 | 12M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -12.9M |
| 0.80 | |
| -1.29 | |
| n/a | |
| -1.69 | |
| P/B (ttm) | 0.95 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 1.1 |
| 成交量 | 244,151 |
| 20 日平均成交量 | 616,525 |
| 開盤價 | 1.13 |
| 前收盤價 | 1.13 |
| 當日區間 | 1.08 - 1.13 |
| 52 週範圍 | 0.81 - 4.19 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PHIO
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclin...
完整的公司簡介財報驚奇
Phio Pharmaceuticals 已於 Aug 6, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.36 低於預期 0.00, 年增 20.00% 成長.
